Latest & greatest articles for covid-19

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on covid-19 or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on covid-19 and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for covid-19

161. Efficacy and safety of OM-85 in paediatric recurrent respiratory tract infections which could have a possible protective effect on COVID-19 pandemic: A meta-analysis Full Text available with Trip Pro

Efficacy and safety of OM-85 in paediatric recurrent respiratory tract infections which could have a possible protective effect on COVID-19 pandemic: A meta-analysis Efficacy and safety of OM-85 in paediatric recurrent respiratory tract infections which could have a possible protective effect on COVID-19 pandemic: A meta-analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other (...) advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. National Institutes of Health National Library of Medicine National Center for Biotechnology Information Show account info Close Account Logged in as: username (My NCBI) (My Bibliography) Search: Search Save Email Send to Display options Display options Format Save citation to file Format: Create file Cancel Email citation Subject: To: Format: MeSH and other data Send email Cancel Add to Collections

2021 EvidenceUpdates

162. Efficacy and safety of sofosbuvir/ ledipasvir in treatment of patients with COVID-19; A randomized clinical trial

Efficacy and safety of sofosbuvir/ ledipasvir in treatment of patients with COVID-19; A randomized clinical trial Efficacy and safety of sofosbuvir/ ledipasvir in treatment of patients with COVID-19; A randomized clinical trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation (...) for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Display options Display options Format Share Permalink Copy Page navigation Acta Biomed Actions . 2020 Nov 10;91(4):e2020102. doi: 10.23750/abm.v91i4.10877. Efficacy and safety of sofosbuvir/ ledipasvir in treatment of patients with COVID-19; A randomized clinical trial , , , , , , , Affiliations Expand Affiliations 1 Array. khalilih@tums.ac.ir. 2 Tehran

2021 EvidenceUpdates

163. Managing TB during the COVID-19 Pandemic

Managing TB during the COVID-19 Pandemic Managing TB during the COVID-19 Pandemic | Royal College of Nursing We use cookies to ensure that we give you the best experience on our website. Continue submit Membership Employment and Pay Professional Development Clinical Library Get Involved Get Help News & Events About Quick links × × × × × × × × × × submit Managing TB during the COVID-19 Pandemic You are here: / / / Managing TB during the COVID-19 Pandemic  Hanna Kaur 30 Apr 2020 The COVID-19 (...) pandemic has changed the world significantly in a short space of time, and all of our lives have been affected. The lock down has forced us to live differently and to adapt to different ways of working. It has also had a huge impact on how health care services are delivered such as management and control of Tuberculosis (TB). Due to the COVID-19 pandemic, managing TB has become even more of a challenge. As it has interrupted the ways we reach out to the patients affected by TB. It is vital to have

2021 Royal College of Nursing

164. RCN guidance on vaccination during COVID-19 and the COVID-19 vaccine programmes

RCN guidance on vaccination during COVID-19 and the COVID-19 vaccine programmes COVID-19 vaccination | Public Health | Royal College of Nursing We use cookies to ensure that we give you the best experience on our website. Continue submit Membership Employment and Pay Professional Development Clinical Library Get Involved Get Help News & Events About Quick links × × × × × × × × × × submit COVID-19 vaccination You are here: / / / / COVID-19 vaccination This resource is designed to signpost RCN (...) members to the available information, guidance and relevant RCN positions on the UK COVID-19 vaccine programmes. These include an expansion of the seasonal influenza vaccine programme to include a wider section of the population, with the aim of minimising the risk of co infection with influenza and SARS-CoV2. Alongside the deployment of vaccines for SARS-CoV2 as they are authorised and made available for use across the UK. These programmes require large scale vaccination to ensure that as many people

2021 Royal College of Nursing

165. COVID-19 Vaccine Hesitancy Among Vulnerable Cancer Populations: How SGO Members Can Contribute to the Solution

COVID-19 Vaccine Hesitancy Among Vulnerable Cancer Populations: How SGO Members Can Contribute to the Solution COVID-19 Vaccine Hesitancy Among Vulnerable Cancer Populations: How SGO Members Can Contribute to the Solution | Society of Gynecologic Oncology I'm looking for Search for: Search Close Close Search Box Search Site Toggle Dropdown Search Site Close Menu COVID-19 Vaccine Hesitancy Among Vulnerable Cancer Populations: How SGO Members Can Contribute to the Solution Recommendations (...) Coronavirus Health Equity Jan 25, 2021 Jeffrey F. Hines, MD; Warner K. Huh, MD; Amanda Nickles Fader, MD; Joshua Kesterson, MD; Bhavana Pothuri, MD, MS; Eloise Chapman-Davis, MD; Sandra E. Brooks, MD, MBA The COVID-19 pandemic remains a global health care crisis. However, the development of COVID-19 vaccines, approved for emergency use authorization by the U.S. Food and Drug Administration (FDA) in December 2020, and others in the pipeline, hold the promise of widespread inoculation against the SARS-CoV-2

2021 Society of Gynecologic Oncology

166. Covid-19 and pregnancy

Covid-19 and pregnancy Covid-19 and pregnancy We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Swedish Agency for Health Technology Assessment and Assessment of Social Services Covid-19 and pregnancy Share: Reading time approx. 13 minutes This is an answer from SBU's enquiry service that provides quick answers to narrow questions. The answer compiles scientific studies that examined the risk of serious illness or death from covid (...) -19 during a pregnancy. Question What scientific studies are there on covid-19 effects on pregnant women when it comes to the risk for serious disease, mortality and admission to the ICU? Identified literature Table 1. Systematic reviews with low/medium risk of bias. Included studies Population/Intervention Outcome Allotey et al., 2020 (1) 77 cohort studies (55 comparative, 22 non-comparative) 45 of 77 studies included covid-19 related outcomes Quality Assessment: Newcastle-Ottawa Scale All

2021 Swedish Council on Technology Assessement

167. COVID-19: rapid point of care or near-person testing for service providers

COVID-19: rapid point of care or near-person testing for service providers COVID-19: rapid point of care or near-person testing for service providers - GOV.UK Cookies on GOV.UK We use some essential cookies to make this website work. We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services. We also use cookies set by other sites to help us deliver content from their services. Accept additional cookies Reject additional cookies (...) You can at any time. Hide this message Show or hide search Search on GOV.UK Search Menu National lockdown: stay at home Check what you need to do Guidance COVID-19: rapid point of care or near-person testing for service providers Guidance for service providers on the use and management of COVID-19 rapid point of care or near-person tests and actions to take. Published 1 February 2021 From: Applies to: England Documents HTML Details This guidance describes the main types of coronavirus (COVID-19

2021 Public Health England

168. The ChAdOx1 nCoV-19 covid-19 vaccine from AstraZeneca: great uncertainty over its efficacy

The ChAdOx1 nCoV-19 covid-19 vaccine from AstraZeneca: great uncertainty over its efficacy Prescrire IN ENGLISH - Spotlight ''The ChAdOx1 nCoV-19 covid-19 vaccine from AstraZeneca: great uncertainty over its efficacy'', 29 January 2021 {1} {1} {1} | | > > > The ChAdOx1 nCoV-19 covid-19 vaccine from AstraZeneca: great uncertainty over its efficacy Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |    (...) |   |   |   |  Spotlight The ChAdOx1 nCoV-19 covid-19 vaccine from AstraZeneca: great uncertainty over its efficacy NEWS UPDATE Unlike the first two covid-19 vaccines authorised in Europe, which are messenger RNA vaccines, the covid19 vaccine ChAdOx1 nCoV-19, developed by the University of Oxford and the pharmaceutical company AstraZeneca, is a "viral vector" vaccine. What are the main data available in late January 2021 from the clinical trials of this new vaccine

2021 Prescrire

169. Does Vitamin D help prevent or treat COVID-19?

Does Vitamin D help prevent or treat COVID-19? February 8, 2021 COVID-19 Rapid Reviews Along with regular Tools for Practice, the PEER team will be writing rapid reviews to address COVID-19 topics relevant for primary care. The evidence is changing rapidly and it is possible that as you read this, new evidence will already be available. We will try our best to stay in front and keep you up-to-date during these challenging times. COVID-19 and Vitamin D: Partners in Crime, or Simply Associates (...) ? Clinical Question: Does Vitamin D help prevent or treat COVID- 19? Bottom Line: While observational evidence suggests an association between low vitamin D levels and COVID-19 infection, it is unclear if this is simply reflective of overall health status. There are no randomized, controlled trials (RCTs) assessing vitamin D for prevention of COVID-19 infections. The highest quality RCT of vitamin D treatment during hospitalization did not demonstrate benefit for clinical outcomes. Evidence: • 3 RCTs

2021 Tools for Practice

170. Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians

Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2) | Annals of Internal Medicine LOGIN TO YOUR ACCOUNT or Create a new account Email Can't sign in? Forgot your password? Enter your email address below and we will send you the reset instructions Email (...) , Champaign, Illinois (J.A.J.) , Penn Medicine, Philadelphia, Pennsylvania (M.A.F., M.C.M.) , Penn Medicine, Philadelphia, Pennsylvania (M.A.F., M.C.M.) , Portland Veterans Affairs Medical Center and Oregon Health & Science University, Portland, Oregon (L.L.H.) , Key Question 1 What are the effectiveness and harms of remdesivir in hospitalized patients with coronavirus disease 2019 (COVID-19)? Key Question 2 Do effectiveness and harms in hospitalized patients with COVID-19 vary by symptom duration

2021 American College of Physicians

171. The effect of tocilizumab on mortality in hospitalized patients with COVID-19: a meta-analysis of randomized controlled trials Full Text available with Trip Pro

The effect of tocilizumab on mortality in hospitalized patients with COVID-19: a meta-analysis of randomized controlled trials The effect of tocilizumab on mortality in hospitalized patients with COVID-19: a meta-analysis of randomized controlled trials - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging (...) : Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Review Eur J Clin Pharmacol Actions . 2021 Feb 2;1-6. doi: 10.1007/s00228-021-03087-z. Online ahead of print. The effect of tocilizumab on mortality in hospitalized patients with COVID-19: a meta-analysis of randomized controlled trials

2021 EvidenceUpdates

172. Clinical outcomes of COVID-19 following the use of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers among patients with hypertension in Korea: a nationwide study Full Text available with Trip Pro

Clinical outcomes of COVID-19 following the use of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers among patients with hypertension in Korea: a nationwide study Clinical outcomes of COVID-19 following the use of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers among patients with hypertension in Korea: a nationwide study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features (...) ! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. National Institutes of Health National Library of Medicine National Center for Biotechnology Information Show account info Close Account Logged in as: username (My NCBI) (My Bibliography) Search: Search Save Email Send to Display options Display options Format Save citation to file Format: Create file Cancel Email citation Subject: To: Format: MeSH and other

2021 EvidenceUpdates

173. Real-life validation of the Panbio COVID-19 antigen rapid test (Abbott) in community-dwelling subjects with symptoms of potential SARS-CoV-2 infection Full Text available with Trip Pro

on effectiveness of contact tracing strategies for COVID-19: a modelling study. Lancet Public Heal. 2020;5(8):e452–e459. doi: 10.1016/S2468-2667(20)30157-2. - - - Corman V.M., Landt O., Kaiser M., Molenkamp R., Meijer A., Chu D.K.W. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Eurosurveillance. 2020;25(3):2000045 doi: 10.2807/1560-7917.ES.2020.25.3.2000045. - - - Grant B.D., Anderson C.E., Williford J.R., Alonzo L.F., Glukhova V.A., Boyle D.S. SARS-CoV-2 coronavirus nucleocapsid antigen (...) Real-life validation of the Panbio COVID-19 antigen rapid test (Abbott) in community-dwelling subjects with symptoms of potential SARS-CoV-2 infection Real-life validation of the Panbio™ COVID-19 antigen rapid test (Abbott) in community-dwelling subjects with symptoms of potential SARS-CoV-2 infection - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features

2021 EvidenceUpdates

174. Efficacy of colchicine in non-hospitalized patients with COVID-19 Full Text available with Trip Pro

Efficacy of colchicine in non-hospitalized patients with COVID-19 CDEI - Efficacy of colchicine in non-hospitalized patients with COVID-19 — CDEI Open Menu Close Menu Open Menu Close Menu Feb 6 Written By Note: Preprints are preliminary reports of work that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information (medRxiv). Citation: Tardif, J. C. , Bouabdallaoui (...) , N., L’Allier, P. L., Gaudet, D., Shah, B., Pillinger, M. H., ... & COLCORONA Investigators. (2021). Efficacy of colchicine in non-hospitalized patients with COVID-19. medRxiv . DOI: Clinical trial registry link: Full PICO and Limitations in text: Population: 4488 non-hospitalized patients at least 40 years of age with a confirmed diagnosis of COVID-19. Intervention and Comparator Intervention: 2235 patients. Colchicine (0.5mg po twice daily for the first 3 days then once daily for 27 days

2021 Covid-19 Drug Evidence Initiative

175. Surviving Sepsis Campaign Guidelines on the Management of Adults With Coronavirus Disease 2019 (COVID-19) in the ICU: First Update

Surviving Sepsis Campaign Guidelines on the Management of Adults With Coronavirus Disease 2019 (COVID-19) in the ICU: First Update Surviving Sepsis Campaign Guidelines on the Management of Adults With Coronavirus Disease 2019 (COVID-19) in the ICU: First Update - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging (...) : Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Crit Care Med Actions . 2021 Jan 28. doi: 10.1097/CCM.0000000000004899. Online ahead of print. Surviving Sepsis Campaign Guidelines on the Management of Adults With Coronavirus Disease 2019 (COVID-19) in the ICU: First Update

2021 EvidenceUpdates

176. COVID-19 - SARS-CoV-2

COVID-19 - SARS-CoV-2 1 Chapter 14a - COVID-19 - SARS-Cov-2 Chapter 14a - COVID-19 - SARS-CoV-2 12 February 2021 14a COVID-19 - SARS-CoV-2 NOTIFIABLE The virus COVID-19 disease first emerged as a presentation of severe respiratory infection in Wuhan, China in late 2019 (WHO, 2020). By January 2020, lower respiratory samples taken from affected patients were sequenced and demonstrated a novel coronavirus (SARS-CoV-2) (Huang et al, 2020). The first two cases in the UK were seen in late January (...) transmission is maximal in the first week of illness. Symptomatic and pre-symptomatic transmission (1-2 days before symptom onset), is thought to play a greater role in the spread of SARS-CoV-2 than asymptomatic transmission.2 Chapter 14a - COVID-19 - SARS-Cov-2 Chapter 14a - COVID-19 - SARS-CoV-2 12 February 2021 The disease In adults, the clinical picture varies widely. A significant proportion of individuals are likely to have mild symptoms and may be asymptomatic at the time of diagnosis. Symptoms

2021 The Green Book

177. Performance of the BinaxNOW COVID-19 Antigen Card test relative to the SARS-CoV-2 real-time reverse transcriptase polymerase chain reaction assay among symptomatic and asymptomatic healthcare employees Full Text available with Trip Pro

Performance of the BinaxNOW COVID-19 Antigen Card test relative to the SARS-CoV-2 real-time reverse transcriptase polymerase chain reaction assay among symptomatic and asymptomatic healthcare employees Performance of the BinaxNOW coronavirus disease 2019 (COVID-19) Antigen Card test relative to the severe acute respiratory coronavirus virus 2 (SARS-CoV-2) real-time reverse transcriptase polymerase chain reaction (rRT-PCR) assay among symptomatic and asymptomatic healthcare employees - PubMed (...) This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. National Institutes of Health National Library of Medicine National Center for Biotechnology Information Show account info Close Account Logged in as: username (My NCBI) (My Bibliography) Search: Search Save Email Send to Display options Display

2021 EvidenceUpdates

178. Evaluation of a rapid antigen test (Panbio COVID-19 Ag rapid test device) for SARS-CoV-2 detection in asymptomatic close contacts of COVID-19 patients Full Text available with Trip Pro

Evaluation of a rapid antigen test (Panbio COVID-19 Ag rapid test device) for SARS-CoV-2 detection in asymptomatic close contacts of COVID-19 patients Evaluation of a rapid antigen test (Panbio™ COVID-19 Ag rapid test device) for SARS-CoV-2 detection in asymptomatic close contacts of COVID-19 patients - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features (...) are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. National Institutes of Health National Library of Medicine National Center for Biotechnology Information Show account info Close Account Logged in as: username (My NCBI) (My Bibliography) Search: Search Save Email Send to Display options Display options Format Save citation to file Format: Create file Cancel Email citation Subject: To: Format: MeSH and other data Send email Cancel Add to Collections Create a new collection Add

2021 EvidenceUpdates

179. Living Rapid Review Update 12: What is the specific role of daycares and schools in COVID-19 transmission?

Living Rapid Review Update 12: What is the specific role of daycares and schools in COVID-19 transmission? Living Rapid Review Update 12: What is the specific role of daycares and schools in COVID-19 transmission? | Covid-19 Rapid Review | National Collaborating Centre for Methods and Tools This browser does not support PDFs, or the PDF is too large to render. Please download the PDF:

2021 COVID-19 Rapid Evidence Service

180. A Smartphone-read Quantitative Saliva Test for COVID-19

A Smartphone-read Quantitative Saliva Test for COVID-19 1 | P a g e To provide scientific evidence on the effectiveness, safety and cost-effectiveness of smartphone- read saliva tests for the detection of COVID-19. The outbreak of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has caused great impact to health and economy. Globally, as of 3:42pm CET, 10 January 2021, there have been 88,383,771 confirmed cases of COVID-19, including 1,919,126 deaths, reported to WHO. 9 (...) The molecular tests Real-time Reverse Transcription Polymerase Chain Reaction (RT-PCR) technology is the recognised method by the World Health Organization (WHO), US Center for Disease Control (CDC) and Ministry of Health Malaysia (MoH) for confirmation of COVID-19 case but this method require a swab sample and trained staff with time consuming laboratory procedure. 4,9 As a result, there is a delay of hours to many days between when tests are taken, and results are obtained. Thus, to expand COVID-19

2021 MaHTAS Covid-19 Rapid Evidence Updates